Posted by Michael Wonder on 27 Mar 2023
Health Canada authorises Imbruvica (ibrutinib) in a fixed duration combination with venetoclax for adult patients with previously untreated chronic lymphocytic leukaemia
23 March 2023 - All oral, once daily, fixed duration combination regimen authorised for first-line treatment of CLL.
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that Health Canada has issued a Notice of Compliance authorising the expanded use of Imbruvica (ibrutinib) in a first all oral, fixed duration treatment combination with venetoclax for adults with previously untreated chronic lymphocytic leukaemia, including those with 17p deletion.
